188 related articles for article (PubMed ID: 25321387)
1. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.
Brady V; Thosani S; Zhou S; Bassett R; Busaidy NL; Lavis V
Diabetes Technol Ther; 2014 Dec; 16(12):874-9. PubMed ID: 25321387
[TBL] [Abstract][Full Text] [Related]
2. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Vu K; Busaidy N; Cabanillas ME; Konopleva M; Faderl S; Thomas DA; O'Brien S; Broglio K; Ensor J; Escalante C; Andreeff M; Kantarjian H; Lavis V; Yeung SC
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):355-62. PubMed ID: 22658895
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
6. Permanent insulin-dependent diabetes mellitus in a patient with acute lymphoblastic leukemia.
Akane Y; Yamamoto M; Igarashi K; Takebayashi A; Hori T
Pediatr Int; 2020 Mar; 62(3):403-405. PubMed ID: 32022381
[No Abstract] [Full Text] [Related]
7. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
O'Brien S; Thomas DA; Ravandi F; Faderl S; Pierce S; Kantarjian H
Cancer; 2008 Oct; 113(8):2097-101. PubMed ID: 18720356
[TBL] [Abstract][Full Text] [Related]
8. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
[TBL] [Abstract][Full Text] [Related]
9. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Benton CB; Thomas DA; Yang H; Ravandi F; Rytting M; O'Brien S; Franklin AR; Borthakur G; Dara S; Kwari M; Pierce SR; Jabbour E; Kantarjian H; Garcia-Manero G
Br J Haematol; 2014 Nov; 167(3):356-65. PubMed ID: 25066676
[TBL] [Abstract][Full Text] [Related]
10. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
11. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
[TBL] [Abstract][Full Text] [Related]
12. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
[TBL] [Abstract][Full Text] [Related]
14. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
Shi W; Shi YK; He XH; Zhou SY; Dong M; Zhang CG; Yang JL; Liu P; Qin Y; Yang S; Gui L
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):978-81. PubMed ID: 20646648
[TBL] [Abstract][Full Text] [Related]
15. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
16. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E
Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703
[TBL] [Abstract][Full Text] [Related]
17. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
[TBL] [Abstract][Full Text] [Related]
18. Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.
Damlaj M; Snnallah M; Bashir R; Eddine IS; Alahmari B; Salama H; Alaskar A; Alhejazi A; Alzahrani M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):690-696. PubMed ID: 32636149
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Ramos-Peñafiel CO; Cabrera-García Á; Rozen-Fuller E; González-León G; Balderas C; Kassack-Ipiña JJ; Castellanos-Sinco H; Martínez-Murillo C; Montaño-Figueroa E; Martínez-Tovar A; Olarte-Carrillo I; Santoyo-Sánchez A; Collazo-Jaloma J
Rev Peru Med Exp Salud Publica; 2014; 31(3):525-9. PubMed ID: 25418653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
